---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-161170"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:24:03.262263+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine reports positive Phase 2 data for bitopertin in EPP and updates for DISC-0974 and DISC-3405 at EHA 2024

## Summary
- Bitopertin reduced protoporphyrin IX by 40% in 60 mg group and cut phototoxic reactions by 75.3% (p=0.011) in AURORA trial.
- DISC-0974 showed 68.9% of non-transfusion dependent myelofibrosis patients had hemoglobin response ≥1.5 g/dL; one TD patient became transfusion independent.
- DISC-3405 demonstrated >50% mean serum iron reduction sustained for at least 4 weeks at 300 mg dose in healthy volunteers.
- No serious adverse events reported across all three programs to date.
- Data were presented at European Hematology Association 2024 Congress on June 14, 2024.

## SEC filing metadata
- accession: 0001193125-24-161170
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312524161170/0001193125-24-161170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312524161170/d826950d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-161170
- JSON: https://secwatch.observer/filing/0001193125-24-161170.json
- Plain text: https://secwatch.observer/filing/0001193125-24-161170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.